The FDA has provided approval for the use of Rybelsus® in patients who have been diagnosed with type 2 . With this said, Rybelsus® is usually not a first-line treatment option for people with this condition. Instead, it may be an excellent alternative to other medications generally considered the first line of defense against type 2 diabetes. If the patient has difficulty controlling their sugar levels with first-line medications such as metformin, a physician may consider adding Rybelsus® as an additional medication to their treatment plan.
Our doctors craft tailored solutions for each patient. While Rybelsus® (semaglutide) stands out as a top-tier choice, we believe in empowering our patients to select the treatment that best aligns with their unique health journey. Our physicians, mindful of availability and individual requirements, may recommend or prescribe a different GLP-1 for type 2 diabetes management. Explore these GLP-1 options below:
-
Mounjaro® (tirzepatide): This unique medication has dual GLP-1 and GIP receptor activity. This innovative approach may resonate with patients looking for a holistic strategy for managing their diabetes.
-
Ozempic® (semaglutide): Ozempic® remains a standout with its once-weekly injectable format, delivering reliability and efficiency in blood sugar management. Its ability to reduce cardiovascular risk adds another layer of appeal.
-
Semaglutide: Due to shortages, compounded semaglutide may be prescribed as an alternative to branded Ozempic® as long as it remains on the FDA drug shortages list. Although compounded semaglutide is not FDA-approved, our pharmacy provider complies with pertinent federal and state laws and FDA regulations.*
-
Trulicity® (dulaglutide): Trulicity® also comes with a pre-filled disposable pen for its once-weekly injection, ideal for those who want ease of use without compromising consistent blood sugar control.
-
Victoza® (liraglutide): This daily injectable provides a trusted solution for diabetes management.
-
Bydureon® (exenatide): Bydureon® has an extended-release formulation, requiring just one weekly injection.
For patients with insulin resistance or a semaglutide allergy, your doctor may suggest alternatives to GLP-1 anti-diabetic medications. Individuals with insulin resistance and difficult-to-control sugars may also receive a different medication as part of their treatment plan, such as metformin or NovoLog (insulin aspart). For patients with a semaglutide allergy, medications such as Jardiance (empagliflozin) or Glucotrol (glipizide) may be considered.
*Compounded semaglutide prescriptions are limited to residents in the following states: AZ, CA, CO, DE, FL, GA, HI, IA, ID, IL, KS, MA, MD, ME, MO, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SD, TN, TX, UT, VA, WA, WV, Washington D.C., WY.